IFO-Regina Elena Institute for Cancer Research

Rome 14 trials 7 recruiting

14 Registered trials

7 Currently recruiting

Organisation

IFO-Regina Elena Institute for Cancer Research

Location

Rome, Italy

Identifier

ORL-000005328

Address

Via Chianesi, 53, 00144, Italy

Departments

Ematologia
Medical Oncology
Nuclear Medicine
Oncologia Medica
Oncologia Medica 2
Oncology
S.C. Oncologia Medica A
U.O. Oncologia Medica 2
UOC Oncologia Medica 2

Clinical trials at this site (14)

Search interface

Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation Pending

2024-518386-95-02 Non small-cell lung cancer 4
A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatm… Pending

2024-519087-41-00 Breast cancer is the most common form of cancer among w 5
64CuCl2 PET/CT VS 18F-choline PET/CT in prostate cancer Pending

2025-520861-29-00 Prostate cancer at risk of developing metastatic lesion 5
Use of the diagnostic PET with 64CuCl2 in order to select patients, in which a disease relapse is shown after prostate surgical removal, to … Pending

2025-520868-17-00 Cancer on the prostatic bed 5
A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tum… Pending

2025-521209-42-00 advanced colorectal cancer with wild-type RAS and right 6
Upfront trastuzumab-deruxtecan plus capecitabine and bevacizumab for patients with HER2 positive metastatic colorectal cancer: the CHIMERA t… Recruiting

2024-519479-24-00 metastatic colorectal cancer 4 2025-11-21
A multicenter, Phase II, open label, randomized trial evaluating the efficacy of Tedopi plus docetaxel or Tedopi plus nivolumab as second-li… Recruiting

2024-518224-74-01 metastatic non-small-cell lung cancer 4 2025-02-07
Neoadjuvant chemo-immunotherapy for stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC) Recruiting

2024-519205-35-01 stage III PD-L1 positive Non-Small Cell Lung Cancer (NS 4 2025-07-08
Eltrombopag for the treatment of thrombocytopenia due to low - and intermediate risk myelodysplastic syndromes. Recruiting

2024-520133-72-00 Myelodysplastic syndromes 4 2025-02-05
A study investigating the use of EP0031 in patients with cancers having an abnormal RET gene. Recruiting

2022-501636-42-00 Advanced RET-altered malignancies 9 2023-03-21
A Randomized & Observational phase II trial comparing the activity of TrabectedIn vs gemCitabine in patients with metastatic or locally adva… Recruiting

2024-513820-40-00 Metastatic or locally advanced leiomyosarcoma 4 2021-10-29
Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally adva… Recruiting

2024-513372-18-00 Pre- and post-menopausal women with HR+/HER2- LABC or M 4 2019-10-18
ETOP 22-22 ADEPPT: A study of adagrasib for patients with KRASG12C-mutant non-small cell lung cancer (NSCLC), who are elderly or who are unw… Ended

2023-510463-35-00 Patients with KRASG12C-mutant NSCLC, including patients 4 2023-04-26
Immunotherapy with ipilimumab and nivolumab preceded or not by a targeted therapy with encorafenib and binimetinib Ended

2023-505376-30-00 BRAF V600 mutation–positive unresectable or metastatic 4 2018-10-30